The 15-deoxy-Δ12,14-prostaglandin J2 suppresses monocyte chemoattractant protein-1 expression in IFN-γ-stimulated astrocytes through induction of MAPK phosphatase-1

Journal of Immunology

Volumn 181, Issue 12, 2008, Pages 8642-8649

  Lee, Jee Hoon ^a   Woo, Joo Hong ^a   Woo, Sang Uk ^a   Kim, Kwang Soo ^a   Park, Sang Myun ^a   Joe, Eun Hye ^a   Jou, Ilo ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; GAMMA INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP1; 15 DEOXY DELTA(12,14) PROSTAGLANDIN J2; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J2; AUTACOID; CCL2 PROTEIN, RAT; DRUG DERIVATIVE; PROSTAGLANDIN D2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MECHANISM; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DOWN REGULATION; DRUG ANTAGONISM; ENCEPHALITIS; ENZYME INDUCTION; ENZYMOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; MICROGLIA; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; ASTROCYTES; CELLS, CULTURED; CHEMOKINE CCL2; DOWN-REGULATION; DUAL SPECIFICITY PHOSPHATASE 1; ENCEPHALITIS; ENZYME INDUCTION; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; MICROGLIA; PPAR GAMMA; PROSTAGLANDIN D2; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP-1;

EID: 58849101326     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.12.8642     Document Type: Article

References (46)

1. Betmouni, S., V. H. Perry, and J. L. Gordon. 1996. Evidence for an early inflammatory response in the central nervous system of mice with scrapie. Neuroscience 74: 1-5. (Pubitemid 26291142)
2. McGeer, P. L., and J. Rogers. 1992. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 42: 447-449.
3. Rogers, S. A., S. B. Miller, and M. R. Hammerman. 1996. Altered EGF expression and thyroxine metabolism in kidneys following acute ischemic injury in rat. Am. J. Physiol. 270: F21-F30.
4. Farina, C., F. Aloisi, and E. Meinl. 2007. Astrocytes are active players in cerebral innate immunity. Trends Immunol. 28: 138-145. (Pubitemid 46283692)
5. Kreutzberg, G. W. 1996. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19: 312-318.
6. Huang, D., Y. Han, M. R. Rani, A. Glabinski, C. Trebst, T. Sorensen, M. Tani, J. Wang, P. Chien, S. O'Bryan, et al. 2000. Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation. Immunol. Rev. 177: 52-67.
7. Rankine, E. L., P. M. Hughes, M. S. Botham, V. H. Perry, and L. M. Felton. 2006. Brain cytokine synthesis induced by an intraparenchymal injection of LPS is reduced in MCP-1-deficient mice prior to leukocyte recruitment. Eur. J. Neurosci. 24: 77-86.
8. Belmadani, A., P. B. Tran, D. Ren, and R. J. Miller. 2006. Chemokines regulate the migration of neural progenitors to sites of neuroinflammation. J. Neurosci. 26: 3182-3191.
9. Felton, L. M., C. Cunningham, E. L. Rankine, S. Waters, D. Boche, and V. H. Perry. 2005. MCP-1 and murine prion disease: separation of early behavioral dysfunction from overt clinical disease. Neurobiol. Dis. 20: 283-295.
10. -/-ice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394: 894-897.
11. Gu, L., Y. Okada, S. K. Clinton, C. Gerard, G. K. Sukhova, P. Libby, and B. J. Rollins. 1998. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell 2: 275-281.
12. Wang, X., T. L. Yue, F. C. Barone, and G. Z. Feuerstein. 1995. Monocyte chemoattractant protein-1 messenger RNA expression in rat ischemic cortex. Stroke 26: 661-666.
13. Scher, J. U., and M. H. Pillinger. 2005. 15d-PGJ2: the anti-inflammatory prostaglandin? Clin. Immunol. 114: 100-109.
14. Lawrence, T., D. A. Willoughby, and D. W. Gilroy. 2002. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat. Rev. 2: 787-795. (Pubitemid 37328718)
15. Jiang, C., A. T. Ting, and B. Seed. 1998. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86.
16. 2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J. Clin. Invest. 106: 189-197.
17. Su, C. G., X. Wen, S. T. Bailey, W. Jiang, S. M. Rangwala, S. A. Keilbaugh, A. Flanigan, S. Murthy, M. A. Lazar, and G. D. Wu. 1999. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J. Clin. Invest. 104: 383-389.
18. 2 ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168: 2508-2515.
19. 2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J. Cereb. Blood Flow Metab. 26: 218-229.
20. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc. Natl. Acad. Sci. USA 97: 4844-4849.
21. Park, E. J., S. Y. Park, E. H. Joe, and I. Jou. 2003. 15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. J. Biol. Chem. 278: 14747-14752.
22. Kim, K. S., H. Y. Kim, E. H. Joe, and I. Jou. 2008. Matrix metalloproteinase-3 induction in rat brain astrocytes: focus on the role of two AP-1 elements. Biochem. J. 410: 605-611.
23. Shang, Y., X. Hu, J. DiRenzo, M. A. Lazar, and M. Brown. 2000. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103: 843-852.
24. Bennett, B. L., D. T. Sasaki, B. W. Murray, E. C. O'Leary, S. T. Sakata, W. Xu, J. C. Leisten, A. Motiwala, S. Pierce, Y. Satoh, et al. 2001. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA 98: 13681-13686.
25. Blume, S. W., R. C. Snyder, R. Ray, S. Thomas, C. A. Koller, and D. M. Miller. 1991. Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J. Clin. Invest. 88: 1613-1621.
26. Jia, Z., J. Zhang, D. Wei, L. Wang, P. Yuan, X. Le, Q. Li, J. Yao, and K. Xie. 2007. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res. 67: 4878-4885.
27. Davis, R. J. 2000. Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
28. Dickinson, R. J., and S. M. Keyse. 2006. Diverse physiological functions for dual-specificity MAP kinase phosphatases. J. Cell Sci. 119: 4607-4615.
29. Chawla, A., Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans. 2001. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7: 48-52.
30. 2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF-κBp300 pathway independent of peroxisome proliferator-activated receptor γ. J. Immunol. 173: 5196-5208.
31. Rovin, B. H., J. A. Dickerson, L. C. Tan, and C. A. Hebert. 1995. Activation of nuclear factor-κB correlates with MCP-1 expression by human mesangial cells. Kidney Int. 48: 1263-1271.
32. Duque, N., C. Gomez-Guerrero, and J. Egido. 1997. Interaction of IgA with Fcα receptors of human mesangial cells activates transcription factor nuclear factor-κB and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible protein 10. J. Immunol. 159: 3474-3482. (Pubitemid 127482106)
33. Ruiz-Ortega, M., C. Bustos, M. A. Hernandez-Presa, O. Lorenzo, J. J. Plaza, and J. Egido. 1998. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-κB activation and monocyte chemoattractant protein-1 synthesis. J. Immunol. 161: 430-439. (Pubitemid 28285552)
34. Hisada, Y., H. Sakurai, and T. Sugaya. 2000. Cell to cell interaction between mesangial cells and macrophages induces the expression of monocyte chemoattractant protein-1 through nuclear factor-κB activation. Biochem. Biophys. Res. Commun. 269: 309-316.
35. Yamada, M., S. Kim, K. Egashira, M. Takeya, T. Ikeda, O. Mimura, and H. Iwao. 2003. Molecular mechanism and role of endothelial monocyte chemoattractant protein-1 induction by vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 23: 1996-2001.
36. Nakayama, K., A. Furusu, Q. Xu, T. Konta, and M. Kitamura. 2001. Unexpected transcriptional induction of monocyte chemoattractant protein 1 by proteasome inhibition: involvement of the c-Jun N-terminal kinase-activator protein 1 pathway. J. Immunol. 167: 1145-1150. (Pubitemid 32703107)
37. Ping, D., G. Boekhoudt, F. Zhang, A. Morris, S. Philipsen, S. T. Warren, and J. M. Boss. 2000. Sp1 binding is critical for promoter assembly and activation of the MCP-1 gene by tumor necrosis factor. J. Biol. Chem. 275: 1708-1714.
38. +cells via mitogen-activated protein kinase-dependent and NF-κB-independent pathways. Int. Immunol. 17: 1525-1531.
39. Zhao, Q., X. Wang, L. D. Nelin, Y. Yao, R. Matta, M. E. Manson, R. S. Baliga, X. Meng, C. V. Smith, J. A. Bauer, et al. 2006. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J. Exp. Med. 203: 131-140.
40. Chen, P., J. Li, J. Barnes, G. C. Kokkonen, J. C. Lee, and Y. Liu. 2002. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J. Immunol. 169: 6408-6416. (Pubitemid 36903490)
41. Eljaschewitsch, E., A. Witting, C. Mawrin, T. Lee, P. M. Schmidt, S. Wolf, H. Hoertnagl, C. S. Raine, R. Schneider-Stock, R. Nitsch, and O. Ullrich. 2006. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49: 67-79.
42. Price, D. M., D. L. Terriff, C. L. Chik, and A. K. Ho. 2007. The role of protein turnover in regulating MKP-1 levels in rat pinealocytes. Mol. Cell. Endocrinol. 263: 134-141.
43. Kassel, O., A. Sancono, J. Kratzschmar, B. Kreft, M. Stassen, and A. C. Cato. 2001. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J. 20: 7108-7116. (Pubitemid 34062302)
44. Chu, S., and T. J. Ferro. 2005. Sp1: regulation of gene expression by phosphorylation. Gene 348: 1-11.
45. Sun, Y., S. P. Alexander, M. J. Garle, C. L. Gibson, K. Hewitt, S. P. Murphy, D. A. Kendall, and A. J. Bennett. 2007. Cannabinoid activation of PPAR α; a novel neuroprotective mechanism. Br. J. Pharmacol. 152: 734-743.
46. Fu, J., F. Oveisi, S. Gaetani, E. Lin, and D. Piomelli. 2005. Oleoylethanolamide, an endogenous PPAR-αagonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology 48: 1147-1153.